KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$35.0 million.

  • Nektar Therapeutics' Income from Continuing Operations rose 558.33% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.4 million, marking a year-over-year increase of 3263.14%. This contributed to the annual value of -$119.0 million for FY2024, which is 5689.72% up from last year.
  • As of Q3 2025, Nektar Therapeutics' Income from Continuing Operations stood at -$35.0 million, which was up 558.33% from -$39.2 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Income from Continuing Operations registered a high of $7.2 million during Q4 2024, and its lowest value of -$159.1 million during Q2 2022.
  • For the 5-year period, Nektar Therapeutics' Income from Continuing Operations averaged around -$74.5 million, with its median value being -$52.4 million (2024).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 5689.88% in 2021, then soared by 11719.15% in 2024.
  • Over the past 5 years, Nektar Therapeutics' Income from Continuing Operations (Quarter) stood at -$146.9 million in 2021, then skyrocketed by 54.66% to -$66.6 million in 2022, then surged by 36.82% to -$42.1 million in 2023, then skyrocketed by 117.19% to $7.2 million in 2024, then tumbled by 583.66% to -$35.0 million in 2025.
  • Its Income from Continuing Operations was -$35.0 million in Q3 2025, compared to -$39.2 million in Q2 2025 and -$46.4 million in Q1 2025.